Schizophrenia Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Otsuka Pharma, Gedeon Richter Ltd., Lyndra Therapeutics, Neurocrine Bioscience, Takeda

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Schizophrenia pipeline constitutes 70+ key companies continuously working towards developing 70+ Schizophrenia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Schizophrenia Pipeline Insight, 2024 [https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Schizophrenia Market.

The Schizophrenia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Schizophrenia Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Schizophrenia treatment therapies with a considerable amount of success over the years.

*
Schizophrenia companies working in the treatment market are Midatech, Addex Therapeutics, Autifony Therapeutics, MapLight Therapeutics, Cyclerion Therapeutics, Valentech LLC, Roche, Merck Sharp & Dohme, Cerevel Therapeutics, Boehringer Ingelheim, Sunovion Pharmaceuticals, Karuna Therapeutics, and others, are developing therapies for the Schizophrenia treatment

*
Emerging Schizophrenia therapies such as - MTD211, M4 PAM, Back up modulators, ML-007, CY 6463, VLT-015, Ralmitaront, MK-8189, Emraclidine, Iclepertin, Ulotaront, KarXT, and others are expected to have a significant impact on the Schizophrenia market in the coming years.

*
In August 2023, Sumitomo Pharma revealed disappointing results as two Phase III trials targeting schizophrenia failed to achieve their primary goals. These trials, named DIAMOND 1 and DIAMOND 2, assessed ulotaront's efficacy in managing acute psychosis among adults diagnosed with schizophrenia. Ulotaront, possessing trace amine-associated receptor 1 (TAAR1) agonist properties alongside 5-HT1A agonist activity, was the focus of investigation. Notably, Otsuka Pharmaceutical collaborates with Sumitomo Pharma in the co-development of this drug candidate.

*
In March 2023, Positive topline results from the Phase 3 EMERGENT-3 trial, which examined the effectiveness, safety, and tolerability of KarXT (xanomeline-trospium), the company's flagship experimental medication, in adults with schizophrenia, were released by Karuna Therapeutics

Schizophrenia Overview

Schizophrenia is a chronic and severe mental disorder characterized by disruptions in thought processes, perceptions, emotions, and behavior. People with schizophrenia may experience hallucinations (seeing or hearing things that others do not), delusions (false beliefs), disorganized thinking and speech, reduced expression of emotions, and social withdrawal.

Get a Free Sample PDF Report to know more about Schizophrenia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight [https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Schizophrenia Drugs Under Different Phases of Clinical Development Include:

*
MTD211: Midatech

*
M4 PAM: Addex Therapeutics

*
Back up modulators: Autifony Therapeutics

*
ML-007: MapLight Therapeutics

*
Luvadaxistat: Takeda

*
CY6463: Cyclerion Therapeutics

*
AVP 786: Avanir Pharmaceuticals

*
CY 6463: Cyclerion Therapeutics

*
VLT-015: Valentech LLC

*
Ralmitaront: Roche

*
MK-8189: Merck Sharp & Dohme

*
Emraclidine: Cerevel Therapeutics

*
Iclepertin: Boehringer Ingelheim

*
Ulotaront: Sunovion Pharmaceuticals

*
KarXT: Karuna Therapeutics

Route of Administration

Schizophrenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Inhalation

*
Inhalation/Intravenous/Oral

*
Intranasal

*
Intravenous

*
Intravenous/ Subcutaneous

*
NA

*
Oral

*
Oral/intranasal/subcutaneous

*
Parenteral

*
Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

*
Antibody

*
Antisense oligonucleotides

*
Immunotherapy

*
Monoclonal antibody

*
Peptides

*
Protein

*
Recombinant protein

*
Small molecule

*
Stem Cell

*
Vaccine

Schizophrenia Pipeline Therapeutics Assessment

*
Schizophrenia Assessment by Product Type

*
Schizophrenia By Stage and Product Type

*
Schizophrenia Assessment by Route of Administration

*
Schizophrenia By Stage and Route of Administration

*
Schizophrenia Assessment by Molecule Type

*
Schizophrenia by Stage and Molecule Type

DelveInsight's Schizophrenia Report covers around 70+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Schizophrenia product details are provided in the report. Download the Schizophrenia pipeline report to learn more about the emerging Schizophrenia therapies [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Schizophrenia Therapeutics Market include:

Key companies developing therapies for Schizophrenia are - Otsuka Pharmaceutical Development & Commercialization, Inc., Gedeon Richter Ltd., Lyndra Therapeutics, Neurocrine Bioscience, Takeda Pharmaceutical Company, Memory Pharmaceuticals, Hoffmann-La Roche, Neurocrine Biosciences, Boehringer Ingelheim, Meiji Seika Pharma Co., Ltd., SK Life Science, Inc., Alkermes, Inc. , Solvay Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, SyneuRx International (Taiwan) Corp, BioXcel Therapeutics Inc, Cognitive Research Corporation, Amarex Clinical Research, Forum Pharmaceuticals Inc, Amneal Pharmaceuticals, LLC, Recognify Life Sciences, Accutest Research Laboratories (I) Pvt. Ltd., Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Janssen, LP, Delpor, Inc., Jiangsu Hansoh Pharmaceutical, Cerevel Therapeutics, LLC, Zogenix, Inc., Luye Pharma, Reviva Pharmaceuticals, Alkermes, Inc., Karuna Therapeutics, Autifony Therapeutics, Neumora Therapeutics, Adex Therapeutics, and others.

Schizophrenia Pipeline Analysis:

The Schizophrenia pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Schizophrenia with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Schizophrenia Treatment.

*
Schizophrenia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Schizophrenia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Schizophrenia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Schizophrenia drugs and therapies [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Schizophrenia Pipeline Market Drivers

*
Emergence of second and third generation anti-phsychotics, increasing need for better and effective treatment are some of the important factors that are fueling the Schizophrenia Market.

Schizophrenia Pipeline Market Barriers

*
However, lack of understanding of disease etiology and pathophysiology, patent expiry of major drugs and other factors are creating obstacles in the Schizophrenia Market growth.

Scope of Schizophrenia Pipeline Drug Insight

*
Coverage: Global

*
Key Schizophrenia Companies: Midatech, Addex Therapeutics, Autifony Therapeutics, MapLight Therapeutics, Cyclerion Therapeutics, Valentech LLC, Roche, Merck Sharp & Dohme, Cerevel Therapeutics, Boehringer Ingelheim, Sunovion Pharmaceuticals, Karuna Therapeutics, and others

*
Key Schizophrenia Therapies: MTD211, M4 PAM, Back up modulators, ML-007, CY 6463, VLT-015, Ralmitaront, MK-8189, Emraclidine, Iclepertin, Ulotaront, KarXT, and others

*
Schizophrenia Therapeutic Assessment: Schizophrenia current marketed and Schizophrenia emerging therapies

*
Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers

Request for Sample PDF Report for Schizophrenia Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1

Schizophrenia Report Introduction

2

Schizophrenia Executive Summary

3

Schizophrenia Overview

4

Schizophrenia- Analytical Perspective In-depth Commercial Assessment

5

Schizophrenia Pipeline Therapeutics

6

Schizophrenia Late Stage Products (Phase II/III)

7

Schizophrenia Mid Stage Products (Phase II)

8

Schizophrenia Early Stage Products (Phase I)

9

Schizophrenia Preclinical Stage Products

10

Schizophrenia Therapeutics Assessment

11

Schizophrenia Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Schizophrenia Key Companies

14

Schizophrenia Key Products

15

Schizophrenia Unmet Needs

16

Schizophrenia Market Drivers and Barriers

17

Schizophrenia Future Perspectives and Conclusion

18

Schizophrenia Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=schizophrenia-pipeline-drugs-analysis-report-2024-fda-approvals-clinical-trials-therapies-by-delveinsight-otsuka-pharma-gedeon-richter-ltd-lyndra-therapeutics-neurocrine-bioscience-takeda]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.